000 01536 a2200433 4500
005 20250517014620.0
264 0 _c20160126
008 201601s 0 0 eng d
022 _a1538-8514
024 7 _a10.1158/1535-7163.MCT-14-0924
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLeonard, John E
245 0 0 _aNonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody.
_h[electronic resource]
260 _bMolecular cancer therapeutics
_cApr 2015
300 _a964-72 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAnimals
650 0 4 _aAntibodies, Monoclonal, Humanized
_xadministration & dosage
650 0 4 _aAntigens, CD
_xmetabolism
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aDose-Response Relationship, Drug
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aKiller Cells, Natural
_xdrug effects
650 0 4 _aLymphocyte Count
650 0 4 _aMacaca fascicularis
650 0 4 _aMale
650 0 4 _aRats
650 0 4 _aSemaphorins
_xantagonists & inhibitors
650 0 4 _aT-Lymphocytes
_xdrug effects
700 1 _aFisher, Terrence L
700 1 _aWinter, Laurie A
700 1 _aCornelius, Chad A
700 1 _aReilly, Christine
700 1 _aSmith, Ernest S
700 1 _aZauderer, Maurice
773 0 _tMolecular cancer therapeutics
_gvol. 14
_gno. 4
_gp. 964-72
856 4 0 _uhttps://doi.org/10.1158/1535-7163.MCT-14-0924
_zAvailable from publisher's website
999 _c24599914
_d24599914